SynBioBeta Speaker
Da Lin
General Biotechnologies
Principal Scientist
Dr Da Lin is the Principal Scientist at General Biotechnologies where he leads the Molecular Biology team building a pipeline of oral GLP-1 peptides delivered inside cyanobacterial cells. Da has a PhD from the University of Oxford, is a former postdoctoral Immunologist and a two-time founder of SynBio spinouts in the field of DNA assembly technology and Epigenetics.
Sessions Featuring
Da
This Year
•
-
Biomanufacturing
Can Edible Microbes Slash the Cost of Oral GLP-1s?
The oral GLP-1 challenge is, at its core, a manufacturing cost problem. Downstream purification consumes up to 80% of manufacturing cost, and because peptides are readily digested in the stomach, oral formulations of the same drug demands 50-200-fold higher doses than injection to achieve the same effect. General Biotechnologies is building an edible microbes that can express GLP-1 inside the cell itself — making the organism both a low-cost factory and drug delivery vehicle. The cell wall acts as a natural capsule, shielding up to 99% of the peptide payload from stomach acid and enzymes, before releasing it progressively in the intestine for a sufficient dose to be absorbed into the blood.
•
-
Biomanufacturing
Can Edible Microbes Slash the Cost of Oral GLP-1s?
The oral GLP-1 challenge is, at its core, a manufacturing cost problem. Downstream purification consumes up to 80% of manufacturing cost, and because peptides are readily digested in the stomach, oral formulations of the same drug demands 50-200-fold higher doses than injection to achieve the same effect. General Biotechnologies is building an edible microbes that can express GLP-1 inside the cell itself — making the organism both a low-cost factory and drug delivery vehicle. The cell wall acts as a natural capsule, shielding up to 99% of the peptide payload from stomach acid and enzymes, before releasing it progressively in the intestine for a sufficient dose to be absorbed into the blood.
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
